Amifostine selectively protects healthy tissues in radiotherapy without affecting the efficiency of the treatment. Moreover, reduces the incidence of xerostomy and mucositis in head and neck cancer treatments. In in vitro studies, at concentrations 20 to 240 higher than those used in radiotherapy, amifostine reduces the frequency of chromosome aberrations induced by ionising radiation. The aim of the present project is to study if amifostine, at therapeutic concentrations, reduces the frequency of chromosome aberrations in lymphocytes of head and neck cancer patients treated with radiotherapy. In this sense, the study will comprise a group of 22 patients affected by head and neck tumours, receiving 11 of them radiotherapy in combination with amifostine and only radiotherapy the rest. The evaluation of the amifostine effect will be carried out by cytogenetic techniques like uniform stain and in situ fluorescent hybridisation. On one hand, irradiated samples of each patient will be used to determine if any patient show an in vitro hypersensitivity to ionising radiation. On the other hand a full follow-up cytogenetic study on peripheral blood lymphocytes will be performed during and after radiotherapy, in order to know if there are differences in the response to the treatment between the patients receiving or not amifostine. The radioprotector effect on the saliva gland will be valorated by the incidence and gravity of xerostomy and mucositis, and the relationship between the clinical and cytogenetic results will be also analysed.
|Effective start/end date||29/11/03 → 28/11/06|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.